LPGAT1: A Potential Drug Target and Biomarker (G9926)

Target Name: LPGAT1

NCBI ID: G9926

LPGAT1

LPGAT1: A Potential Drug Target and Biomarker

LPGAT1 (long non-coding RNA) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. LPGAT1 is a member of the long non-coding RNA family 34 (LNCLR/POMS), which includes around 1,700 known non-coding RNAs in humans. LPGAT1 is unique due to its sequence similarity with other non-coding RNAs, particularly those in the POMS family.

The POMS family is characterized by the presence of a specific motif, known as the POMS motif, which is a core element composed of a specific amino acid sequence that is conserved across different species. The POMS motif is present in many non-coding RNAs, including LPGAT1, and is thought to play a role in their stability and translation into protein.

LPGAT1 is a 24.1 kilobase (kb) RNA molecule that is expressed in various tissues and cells in the human body. It is primarily localized to the cytoplasm of cells and is not detectable in the nucleus. LPGAT1 is a good candidate for a drug target due to its unique structure and the potential impact it could have on various cellular processes.

Potential Drug Target

One of the main potential drug targets for LPGAT1 is its role in the regulation of cellular processes that are associated with various diseases, such as cancer, neurodegenerative diseases, and autoimmune diseases. LPGAT1 has been shown to be involved in several cellular processes that are linked to the development and progression of these diseases.

For example, LPGAT1 has been shown to be involved in the regulation of cell proliferation, apoptosis (programmed cell death), and translation. In addition, LPGAT1 has been linked to the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

LPGAT1 has also been shown to be involved in the regulation of inflammation, which is a key factor in the development of many diseases, including cancer. LPGAT1 has been shown to be involved in the regulation of immune cell function and the production of pro-inflammatory cytokines.

Biomarker

LPGAT1 has also been identified as a potential biomarker for several diseases. For example, LPGAT1 has been shown to be downregulated in various tissues and cells that are affected by cancer, including breast cancer and colon cancer. This suggests that LPGAT1 may be a useful biomarker for the diagnosis and treatment of these diseases.

In addition, LPGAT1 has also been shown to be involved in the regulation of cellular processes that are associated with aging and age-related diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that LPGAT1 may be a useful biomarker for the diagnosis and treatment of these diseases.

Conclusion

LPGAT1 is a non-coding RNA molecule that is characterized by its sequence similarity with other non-coding RNAs, particularly those in the POMS family. LPGAT1 is a potential drug target and biomarker due to its unique structure and the potential impact it could have on various cellular processes that are associated with the development and progression of diseases. Further research is needed to fully understand the role of LPGAT1 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Lysophosphatidylglycerol Acyltransferase 1

Functions: Lysophospholipid acyltransferase involved in fatty acyl chain remodeling of glycerophospholipids in the endoplasmic reticulum membrane (By similarity). Selectively catalyzes the transfer and esterification of saturated long-chain fatty acids from acyl-CoA to the sn-1 position of 1-lyso-2-acyl phosphatidylethanolamines (1-lyso-PE, LPE), with a preference for stearoyl CoA over palmitoyl CoA as acyl donor (PubMed:36049524). Acts in concert with an unknown phospholipase A1 to convert palmitate phosphatidylethanolamine (PE) species into stearate ones. Provides substrates to the PE methylation pathway, controlling stearate/palmitate composition of PE and phosphatidylcholine (PC) species with an overall impact on de novo hepatic lipid synthesis, body fat content and life span (By similarity). Can acylate lysophosphatidylglycerols (LPG) using various saturated fatty acyl-CoAs as acyl donors (PubMed:15485873). Can also acylate monoacylglycerols with a preference for 2-monoacylglycerols over 1-monoacylglycerols (By similarity). Has no activity toward lysophosphatidic acids (LPA) (By similarity)

The "LPGAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LPGAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets